Acrospire Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Acrospire Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,137	Closed	-$68K	–	2574
2016 Q4	$68K	Buy	3,137 +2,437	+348%	+$61.6K	0.03%	1195
2016 Q3	$18K	Buy	700 +400	+133%	+$7.94K	0.01%	1541
2016 Q2	$6K	Buy	+300	New	+$5.83K	﹤0.01%	1844

Other funds holding RETA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LFWA

LBJ Family Wealth Advisors Austin, Texas $196M AUM 22.12% 1-Year Est. Return

Acrospire Investment Management's RETA Position: Q1 2017 in Review

Acrospire Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2017, closing a stake of 3,137 shares — an estimated $68K sold.

Acrospire Investment Management first reported a position in RETA in Q2 2016 and held it in 3 quarters. The position peaked at $68K in Q4 2016. 55 funds tracked by Wall St. Rank hold RETA as of Q1 2017.

Acrospire Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2017 after selling out during the quarter.
Acrospire Investment Management sold 3,137 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2017, an estimated $68K.
Acrospire Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 3 quarters.
Acrospire Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $68K in Q4 2016.
55 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.